Traders should monitor the upcoming FDA decision on June 20, 2026, and progress on the Phase 3 vaping trial initiation. The Adare manufacturing partnership de-risks supply chain execution ahead of potential launch, but continued high G&A suggests elevated pre-commercial spending that could pressure cash runway if approval is delayed.
Price Chart
Executive Summary
Achieve Life Sciences reported Q4 and full-year 2025 financial results, highlighted by a net loss of $14.7M for the quarter and $54.7M for the year, while maintaining $36.4M in cash. The company advanced its cytisinicline program with FDA acceptance of its NDA for smoking cessation (PDUFA date June 20, 2026), secured a U.S. manufacturing partnership with Adare Pharma Solutions to support a potential 2027 launch, and published key clinical data reinforcing efficacy across multiple patient populations.
Key Financial Metrics
Key Facts
- FDA accepted cytisinicline NDA for smoking cessation with PDUFA date of June 20, 2026
- Partnered with U.S.-based Adare Pharma Solutions for commercial manufacturing, aiming to reduce supply chain risk and costs
- Cash, cash equivalents, and marketable securities totaled $36.4 million as of December 31, 2025
- Total net loss was $14.7 million for Q4 2025 and $54.7 million for the full year
- Cytisinicline received FDA Commissioner’s National Priority Voucher for vaping cessation, enabling expedited review upon submission
- Published positive long-term safety data from ORCA-OL trial and efficacy results in COPD patients in peer-reviewed journals
Financial Impact
Operating expenses increased to $54.9M in 2025 from $39.1M in 2024, driven by higher G&A; R&D spending remained flat. Net loss expanded slightly year-over-year despite stable R&D, reflecting increased commercial readiness investments.
Risk Factors
- FDA may not approve cytisinicline by the PDUFA date, especially given recent inspection observations at one manufacturing site
- Cash of $36.4M may not be sufficient to fund operations through commercial launch in 2027 without dilution or financing
- Increased G&A from $16.3M in 2024 to $31.9M in 2025 raises concerns about cost discipline ahead of revenue generation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.49 (−10.36%) |
Oct 1, 2026 24d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.49 (−10.36%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.49 (+13.47%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.49 (−2.99%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.49 (+4.14%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.49 (−2.41%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.49 (−17.57%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.49 (+29.03%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.49 (−38.38%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.49 (+45.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers